Optimizerx Corporation (OPRX)
NASDAQ:OPRX
Want to see OPRX full AI Analyst Report?
Top Page
OptimizeRx
(NASDAQ:OPRX)
Select Model
Select Model
Rating:63Neutral
Price Target:
$5.50
▼(-23.29% Downside)
Action:Reiterated
Date:06/13/26
The score is supported by a strong balance sheet and a clear profitability reset, reinforced by margin/expense improvements and refinancing benefits discussed on the latest call. The main constraints are weak/declining revenue trends and mixed cash flow near-term, and the stock’s technical setup remains bearish with price below key long-term moving averages.
Positive Factors
Conservative Balance Sheet
Extremely low leverage and a sizable equity base provide durable financial flexibility. With minimal debt after recent paydowns and a new credit facility, OptimizeRx can absorb client churn, fund product investments or opportunistic M&A, and withstand cyclical headwinds without immediate refinancing pressure.
Negative Factors
Top-line Weakness & Guidance Cut
A sustained decline in reported revenue and lower full-year guidance signal durable top-line pressure. Persistent revenue contraction reduces headroom for growth investments, complicates multi-quarter recovery, and forces management to prioritize margin preservation over market-share expansion absent clear demand recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Extremely low leverage and a sizable equity base provide durable financial flexibility. With minimal debt after recent paydowns and a new credit facility, OptimizeRx can absorb client churn, fund product investments or opportunistic M&A, and withstand cyclical headwinds without immediate refinancing pressure.
Read all positive factors
OptimizeRx (OPRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$99.08M
Dividend YieldN/A
Average Volume (3M)472.95K
Price to Earnings (P/E)14.4
Beta (1Y)1.88
Revenue Growth13.75%
EPS GrowthN/A
CountryUS
Employees128
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.36
Shares Outstanding18,765,076
10 Day Avg. Volume342,960
30 Day Avg. Volume472,951
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.77
Price to Sales (P/S)2.08
P/FCF Ratio12.19
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit1.36
Enterprise Value/Ebitda5.34
Forecast
1Y Price Target
$12.00Price Target Upside67.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.92
Revenue Forecast (FY)$109.34M
OptimizeRx Business Overview & Revenue Model
Company Description
OptimizeRx Corporation is a digital health technology firm delivering a broad spectrum of solutions to life sciences organizations, healthcare providers, and patients. Its core offerings encompass financial messaging and a virtual patient support ...
How the Company Makes Money
OptimizeRx primarily makes money by selling digital engagement and communication services to life sciences (pharmaceutical) companies. Its revenue model is largely B2B and is generated through contracts that allow pharma brands to deliver informat...
OptimizeRx Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The call balanced encouraging operational and margin progress (strong adjusted EBITDA growth, improved gross margins, significant product traction with DAP and subscription growth, refinancing savings, and KPI improvements) against tangible near-term top-line challenges (10% YoY revenue decline, 15-20% contracted revenue shortfall, a major client disruption, reduced cash and negative operating cash flow, and a downward revision to revenue guidance). Management emphasized these headwinds are short-to-intermediate term and highlighted programmatic/DSP initiatives and subscription mix as drivers for 2027 recovery.Positive Updates
Quarterly Revenue and Consensus Outperformance
Q1 revenue was $19.8M, and management stated the quarter exceeded consensus estimates on both top and bottom lines, despite YoY revenue decline.
Negative Updates
Year-over-Year Revenue Decline
Revenue decreased 10% YoY to $19.8M in Q1 2026 from $21.9M in Q1 2025; management cited reduced low-margin managed services, MFN-related budget caution, shorter contract durations, and other macro factors as drivers.
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Revenue and Consensus Outperformance
Q1 revenue was $19.8M, and management stated the quarter exceeded consensus estimates on both top and bottom lines, despite YoY revenue decline.
Read all positive updates
Company Guidance
OptimizeRx updated full‑year 2026 guidance to revenue of $95–100 million while maintaining adjusted EBITDA of $21–25 million, and expects full‑year gross margin in the high‑60% range with revenue weighted roughly 40/60 to the second half; Q1 results included revenue of $19.8M (down 10% y/y from $21.9M), adjusted EBITDA $3.3M (vs $1.5M), GAAP net loss $0.5M ($0.03/share), non‑GAAP net income $2.7M ($0.14/diluted share vs $1.5M/$0.08), operating cash flow of –$0.5M, cash of $20.2M (vs $23.4M), debt $23.6M (with $2.7M principal paid in Q1), and KPIs showing DAP product growth of 60% in Q1 with DAP subscription revenue up 45%, average revenue per top‑20 pharma $2.8M (top‑20 = 52% of business), net revenue retention of 110%, and revenue per FTE $801K (vs $710K); management also expects ~ $3M of annualized cash operating expense savings (≈ $1M in‑year 2026 benefit, ex‑severance), refinanced to a $25M term loan with a $10M revolver at SOFR+2.25% (vs prior SOFR+8.5%) for roughly $1.5M of annual interest savings, and highlighted programmatic DSP access (DSPs control >80% of digital promo dollars) to drive greater utilization of currently <10% network inventory into 2027.OptimizeRx Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
88
Very Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 107.34M | 109.43M | 92.13M | 71.52M | 62.45M | 61.29M |
| Gross Profit | 74.12M | 69.27M | 59.38M | 42.90M | 38.97M | 35.64M |
| EBITDA | 18.90M | 16.57M | -8.90M | -21.31M | -9.42M | 2.34M |
| Net Income | 6.84M | 5.13M | -20.11M | -17.57M | -11.44M | 378.08K |
Balance Sheet | ||||||
| Total Assets | 167.26M | 176.92M | 171.17M | 183.37M | 134.65M | 140.99M |
| Cash, Cash Equivalents and Short-Term Investments | 20.17M | 23.36M | 13.38M | 13.85M | 74.14M | 84.68M |
| Total Debt | 23.72M | 26.10M | 33.19M | 36.82M | 234.43K | 327.71K |
| Total Liabilities | 37.65M | 48.62M | 54.17M | 56.82M | 8.54M | 9.61M |
| Stockholders Equity | 129.61M | 128.29M | 117.00M | 126.55M | 126.11M | 131.38M |
Cash Flow | ||||||
| Free Cash Flow | 14.33M | 18.66M | 4.78M | -8.11M | 10.41M | 240.04K |
| Operating Cash Flow | 14.38M | 18.71M | 4.89M | -7.24M | 10.65M | 726.04K |
| Investing Cash Flow | 131.00K | 68.00K | -450.00K | -25.34M | -58.18M | -486.00K |
| Financing Cash Flow | -10.92M | -8.80M | -4.91M | 28.22M | -18.95M | 73.92M |
OptimizeRx Technical Analysis
Neutral
7.17
Price Trends
5.88
Negative
7.12
Negative
11.77
Negative
Market Momentum
-0.20
Negative
46.11
Neutral
40.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPRX, the sentiment is Neutral. The current price of 7.17 is above the 20-day moving average (MA) of 5.09, above the 50-day MA of 5.88, and below the 200-day MA of 11.77, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 46.11 is Neutral, neither overbought nor oversold. The STOCH value of 40.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OPRX.
OptimizeRx Risk Analysis
OptimizeRx disclosed 40 risk factors in its most recent earnings report. OptimizeRx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OptimizeRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $766.02M | 38.53 | 5.67% | 0.52% | 6.64% | 6.54% | |
72 Outperform | $225.37M | 17.87 | 8.64% | 9.67% | -1.72% | -21.57% | |
67 Neutral | $1.72B | 83.91 | 1.64% | ― | 7.86% | -2.92% | |
66 Neutral | $391.03M | 86.44 | 2.48% | ― | 0.81% | ― | |
63 Neutral | $99.08M | 14.35 | 5.47% | ― | 13.75% | ― | |
54 Neutral | $372.68M | -4.29 | -140.63% | ― | 20.85% | -18.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
OPRX
OptimizeRx
5.23
-8.54
-62.02%
TBRG
TruBridge
26.12
2.77
11.86%
HSTM
HealthStream
26.13
-1.23
-4.49%
OMCL
Omnicell
37.83
8.61
29.47%
SPOK
Spok Holdings
10.90
-4.49
-29.17%
SOPH
SOPHiA GENETICS
4.88
1.99
68.86%
OptimizeRx Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OptimizeRx Shareholders Expand Equity Plan, Maintain Oversight
Positive
Jun 12, 2026
At its June 9, 2026 annual meeting, OptimizeRx shareholders approved an amendment to the company’s 2021 Equity Incentive Plan, raising the pool of common shares available for equity awards by 1,000,000 to a total of 5,450,000, while rejectin...
Business Operations and StrategyExecutive/Board Changes
OptimizeRx Announces Chief Commercial Officer Transition Agreement
Neutral
Jun 5, 2026
OptimizeRx Corporation disclosed that on May 11, 2026 it agreed with Chief Commercial Officer Theresa Greco to a separation effective June 15, 2026, with a formal Separation and Advisory Agreement signed on June 1, 2026 and scheduled to become eff...
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
OptimizeRx Secures New Credit Facility to Boost Flexibility
Positive
May 12, 2026
On May 7, 2026, OptimizeRx entered a new $35 million senior secured credit facility with Fifth Third Bank, comprising a $25 million term loan and a $10 million revolving line, to refinance its October 2023 Blue Torch term loan, fund potential stoc...
Business Operations and StrategyExecutive/Board Changes
OptimizeRx Adds Microsoft Health Leader to Board
Positive
Apr 9, 2026
On April 8, 2026, OptimizeRx announced the appointment of Mary Varghese Presti, Corporate Vice President and Chief Operating Officer of Microsoft’s Health Life Sciences division, to its board as an independent director. Her addition is part...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.